AFP and hepatocellular carcinoma: Validation cohort (sensitivity/specificity, AUC):HCC vs. other groups:CTC detection panel: 72.5%/95%, 0.88AFP: 57%/90%, 0.77CTC detection panel + AFP: 76%/95%, 0.89Early-stage HCC vs. other groups:CTC detection panel: 71.8%/95%, 0.87AFP: 53.4%/90%, 0.74CTC detection panel + AFP: 80.9%/87%, 0.88AUC in different stages: 0.92 (BCLC 0), 0.86 (BCLC A), 0.91 (BCLC B), 0.86 (BCLC C) In AFP negative patients: 77.7%/95%, 0.89